Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
New England Journal of Medicine · 11.05.2023 · 388 (19) · 1767-1778
DOI: 10.1056/nejmoa2212851 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 11.05.2023. Verfasst von Toni K Choueiri und 18 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harv…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 167-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Exelixis.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School - both in Boston (T.K.C.); the Department of Genito…
ORCID-Profile: Alberto Suarez Zaizar
Förderung
- NCI NIH HHS
- Exelixis
Zitieren
APA
Choueiri, T. K., Powles, T., Albiges, L., Burotto, M., Szczylik, C., Zurawski, B., Yanez Ruiz, E., Maruzzo, M., Suarez Zaizar, A., Fein, L. E., Schutz, F. A., Heng, D. Y. C., Wang, F., Mataveli, F., Chang, Y. L., van Kooten Losio, M., Suarez, C., Motzer, R. J., & COSMIC-313 Investigators (2023). Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. New England Journal of Medicine, 388(19), 1767-1778. https://doi.org/10.1056/nejmoa2212851
Vancouver
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. New England Journal of Medicine. 2023;388(19):1767-1778. doi:10.1056/nejmoa2212851
BibTeX
@article{Choueiri2023,
author = {Choueiri, Toni K and Powles, Thomas and Albiges, Laurence and Burotto, Mauricio and Szczylik, Cezary and Zurawski, Bogdan and Yanez Ruiz, Eduardo and Maruzzo, Marco and Suarez Zaizar, Alberto and Fein, Luis E and Schutz, Fabio A and Heng, Daniel Y C and Wang, Fong and Mataveli, Fabio and Chang, Yu-Lin and van Kooten Losio, Maximiliano and Suarez, Cristina and Motzer, Robert J and COSMIC-313 Investigators, COSMIC-313 Investigators},
title = {Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {19},
pages = {1767--1778},
doi = {10.1056/nejmoa2212851}
}
EUVIMED